Adhera Therapeutics Inc Financials
This page shows Adhera Therapeutics Inc (ATRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Adhera Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Adhera Therapeutics Inc generates $0.67 in operating cash flow (-$1.4M OCF vs -$2.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Adhera Therapeutics Inc reported -$2.1M in net income in fiscal year 2022. This represents an increase of 66.7% from the prior year.
Adhera Therapeutics Inc held $32K in cash against $0 in long-term debt as of fiscal year 2022.
Adhera Therapeutics Inc had 3M shares outstanding in fiscal year 2022. This represents a decrease of 79.7% from the prior year.
Adhera Therapeutics Inc spent $2K on share buybacks in fiscal year 2022, returning capital to shareholders by reducing shares outstanding.
ATRX Income Statement
| Metric | Q3'23 | Q4'21 | Q3'22 | Q4'20 | Q3'21 | Q2'20 | Q1'20 | Q4'19 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $132K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $105K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $27K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $43K | N/A | $232K | N/A | $174K-49.3% | $343K-36.4% | $539K-40.6% | $907K |
| Operating Income | -$269K | N/A | -$232K | N/A | -$194K+45.5% | -$356K+73.1% | -$1.3M+64.8% | -$3.8M |
| Interest Expense | N/A | N/A | N/A | N/A | $31K-11.4% | $35K+75.0% | $20K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.5M | N/A | -$3.7M | N/A | -$539K+40.5% | -$906K+50.7% | -$1.8M+55.0% | -$4.1M |
| EPS (Diluted) | $-0.83 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ATRX Balance Sheet
| Metric | Q3'23 | Q4'21 | Q3'22 | Q4'20 | Q3'21 | Q2'20 | Q1'20 | Q4'19 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $44K-77.5% | $196K+29.8% | $151K+15000.0% | $1K-98.1% | $54K-64.5% | $152K-51.7% | $315K-25.0% | $420K |
| Current Assets | $44K-77.5% | $196K+29.8% | $151K+15000.0% | $1K-98.1% | $54K-64.5% | $152K-51.7% | $315K-25.0% | $420K |
| Cash & Equivalents | $32K-57.4% | $76K-49.7% | $151K+15000.0% | $1K | $0-100.0% | $8K-87.7% | $65K+30.0% | $50K |
| Inventory | N/A | N/A | N/A | N/A | N/A | $232K-10.1% | $258K | $0 |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $94K+138.7% | $39K | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $26.4M+4.2% | $25.3M+24.1% | $20.4M+38.3% | $14.7M+4.7% | $14.1M+6.3% | $13.2M+9.1% | $12.1M+17.9% | $10.3M |
| Current Liabilities | $26.4M+4.2% | $25.3M+24.1% | $20.4M+38.0% | $14.8M+4.9% | $14.1M+6.3% | $13.2M+9.1% | $12.1M+17.9% | $10.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$26.3M-4.8% | -$25.1M-24.0% | -$20.2M-37.3% | -$14.7M-5.1% | -$14.0M-7.1% | -$13.1M-10.7% | -$11.8M-19.7% | -$9.9M |
| Retained Earnings | -$60.0M-13.1% | -$53.0M-4.0% | -$51.0M-14.3% | -$44.6M-1.9% | -$43.8M-2.2% | -$42.8M-3.1% | -$41.5M-5.6% | -$39.3M |
ATRX Cash Flow Statement
| Metric | Q3'23 | Q4'21 | Q3'22 | Q4'20 | Q3'21 | Q2'20 | Q1'20 | Q4'19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29K+90.2% | -$296K-17.9% | -$251K-178.9% | -$90K-1025.0% | -$8K+91.7% | -$96K+75.6% | -$394K+84.5% | -$2.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Financing Cash Flow | $4K-98.3% | $220K-38.9% | $360K+295.6% | $91K | $0-100.0% | $39K-90.5% | $409K+509.0% | -$100K |
| Dividends Paid | $27K | N/A | $381K | N/A | $388K+1.6% | $382K-0.3% | $383K-1.3% | $388K |
| Share Buybacks | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ATRX Financial Ratios
| Metric | Q3'23 | Q4'21 | Q3'22 | Q4'20 | Q3'21 | Q2'20 | Q1'20 | Q4'19 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | -22.7%+3777.3pp | -3800.0%-3820.5pp | 20.4% |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -4210.6%+81056.1pp | -85266.7%-82422.0pp | -2844.7% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -4212.1%+81054.5pp | -85266.7%-82172.7pp | -3093.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8022.5% | N/A | -2476.2% | N/A | -998.2%-402.1pp | -596.0%-12.6pp | -583.5%+388.9pp | -972.4% |
| Current Ratio | 0.000.0 | 0.010.0 | 0.010.0 | 0.000.0 | 0.000.0 | 0.01-0.0 | 0.03-0.0 | 0.04 |
| Debt-to-Equity | -1.000.0 | -1.010.0 | -1.010.0 | -1.000.0 | -1.000.0 | -1.01+0.0 | -1.03+0.0 | -1.04 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$22.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Adhera Therapeutics Inc profitable?
No, Adhera Therapeutics Inc (ATRX) reported a net income of -$2.1M in fiscal year 2022.
What is Adhera Therapeutics Inc's operating cash flow?
Adhera Therapeutics Inc (ATRX) generated -$1.4M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.
What are Adhera Therapeutics Inc's total assets?
Adhera Therapeutics Inc (ATRX) had $79K in total assets as of fiscal year 2022, including both current and long-term assets.
Does Adhera Therapeutics Inc buy back shares?
Yes, Adhera Therapeutics Inc (ATRX) spent $2K on share buybacks during fiscal year 2022, returning capital to shareholders by reducing shares outstanding.
How many shares does Adhera Therapeutics Inc have outstanding?
Adhera Therapeutics Inc (ATRX) had 3M shares outstanding as of fiscal year 2022.
What is Adhera Therapeutics Inc's current ratio?
Adhera Therapeutics Inc (ATRX) had a current ratio of 0.00 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is Adhera Therapeutics Inc's debt-to-equity ratio?
Adhera Therapeutics Inc (ATRX) had a debt-to-equity ratio of -1.00 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Adhera Therapeutics Inc's return on assets (ROA)?
Adhera Therapeutics Inc (ATRX) had a return on assets of -2692.6% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Adhera Therapeutics Inc's cash runway?
Based on fiscal year 2022 data, Adhera Therapeutics Inc (ATRX) had $32K in cash against an annual operating cash burn of $1.4M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Adhera Therapeutics Inc's debt-to-equity ratio negative or unusual?
Adhera Therapeutics Inc (ATRX) has negative shareholder equity of -$22.2M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Adhera Therapeutics Inc's Piotroski F-Score?
Adhera Therapeutics Inc (ATRX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Adhera Therapeutics Inc's earnings high quality?
Adhera Therapeutics Inc (ATRX) has an earnings quality ratio of 0.67x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.